CC
Casdin Capital Portfolio holdings
AUM
$1.1B
1-Year Return
24.98%
This Quarter Return
+11.22%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.1B
AUM Growth
-$126M
(-10%)
Cap. Flow
-$163M
Cap. Flow
% of AUM
-14.81%
Top 10 Holdings %
Top 10 Hldgs %
85.29%
Holding
45
New
1
Increased
9
Reduced
12
Closed
12
Top Buys
| 1 |
Structure Therapeutics
GPCR
|
+$10.9M |
| 2 |
Relay Therapeutics
RLAY
|
+$7.96M |
| 3 |
Eli Lilly
LLY
|
+$6.63M |
| 4 |
Illumina
ILMN
|
+$4.77M |
| 5 |
Prime Medicine
PRME
|
+$2.96M |
Top Sells
| 1 |
Revolution Medicines
RVMD
|
+$29.8M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$28.9M |
| 3 |
BioLife Solutions
BLFS
|
+$21.5M |
| 4 |
Exact Sciences
EXAS
|
+$16.7M |
| 5 |
Intellia Therapeutics
NTLA
|
+$14.2M |
Sector Composition
| 1 | Healthcare | 98.96% |
| 2 | Consumer Staples | 1.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
GeneDx Holdings
WGS
$3.63B
| $324M | 29.48% |
3,507,164
| – | – |
|
|
2
BioLife Solutions
BLFS
$1.28B
| $166M | 15.12% |
7,707,165
-1,000,000
| -11% | -$21.5M |
|
|
3
Revolution Medicines
RVMD
$8.51B
| $106M | 9.68% |
2,887,933
-810,000
| -22% | -$29.8M |
|
4
Standard BioTools
LAB
$504M
| $91.3M | 8.31% |
76,075,636
| – | – |
|
|
5
Illumina
ILMN
$15.3B
| $61.5M | 5.6% |
645,000
+50,000
| +8% | +$4.77M |
|
6
Avidity Biosciences
RNA
$5.29B
| $50.4M | 4.59% |
1,775,000
-270,000
| -13% | -$7.67M |
|
|
VERV
7
DELISTED
Verve Therapeutics
VERV
| $46M | 4.19% |
4,095,571
+100,000
| +3% | +$1.12M |
|
|
8
Relay Therapeutics
RLAY
$709M
| $39.4M | 3.59% |
11,398,574
+2,300,000
| +25% | +$7.96M |
|
9
Alnylam Pharmaceuticals
ALNY
$61.4B
| $26.6M | 2.42% |
81,500
-38,500
| -32% | -$12.6M |
|
|
10
Structure Therapeutics
GPCR
$1.19B
| $25.4M | 2.31% |
1,225,000
+525,000
| +75% | +$10.9M |
|
11
Beam Therapeutics
BEAM
$2.17B
| $24.7M | 2.25% |
1,450,000
+24,438
| +2% | +$416K |
|
12
Neurogene
NGNE
$286M
| $19.4M | 1.76% |
1,295,361
| – | – |
|
13
Codexis
CDXS
$220M
| $17.6M | 1.6% |
7,200,000
-900,000
| -11% | -$2.2M |
|
14
Sarepta Therapeutics
SRPT
$1.87B
| $16.9M | 1.54% |
990,097
+89,314
| +10% | +$1.53M |
|
15
Denali Therapeutics
DNLI
$2.18B
| $12.5M | 1.13% |
890,000
-100,000
| -10% | -$1.4M |
|
16
Hims & Hers Health
HIMS
$11.8B
| $11.5M | 1.04% |
230,000
+30,000
| +15% | +$1.5M |
|
|
MAZE
17
Maze Therapeutics, Inc. Common Stock
MAZE
$1.09B
| $9.31M | 0.85% |
758,857
-187,500
| -20% | -$2.3M |
|
18
Veracyte
VCYT
$2.51B
| $7.47M | 0.68% |
276,308
| – | – |
|
|
19
Eli Lilly
LLY
$681B
| $6.63M | 0.6% |
+8,500
| New | +$6.63M |
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.08M | 0.55% |
650,000
+15,000
| +2% | +$140K |
|
|
SEPN
21
Septerna, Inc. Common Stock
SEPN
$632M
| $5.85M | 0.53% |
553,268
| – | – |
|
22
Guardant Health
GH
$7.13B
| $5.2M | 0.47% |
100,000
-150,000
| -60% | -$7.81M |
|
|
23
Exact Sciences
EXAS
$10.6B
| $4.78M | 0.44% |
90,000
-315,000
| -78% | -$16.7M |
|
|
24
Prime Medicine
PRME
$720M
| $3.87M | 0.35% |
1,567,175
+1,200,000
| +327% | +$2.96M |
|
25
Agios Pharmaceuticals
AGIO
$2.13B
| $3.33M | 0.3% |
100,000
-150,000
| -60% | -$4.99M |
|